ISO5SpecificityQualityControlexvivoOut ofSpec(OOS)ISO8NewChemicalEntity(NCE)Phase1Confidentialityagreement(CDA)ISO9001BioequivalenceNon-disclosureagreement(NDA)Center forDrugEvaluationand Research(CDER)CarcinogenicityPurityPre-ClinicalChemistryManufacturingControls(CMC)FunctionalityIdentityDeviationStabilityINitial TargetedEngagement forRegulatoryAdvice CBERproducTs(INTERACT)505(b)(1)vs.505(b)(2)efficacysingleascendingdoseISO7AdverseeventCenter forBiologicsEvaluationand Research(CBER)21 CFRPart 31221 CFRPart 11EuropeanMedicinsAgency(EMA)21 CFRPart 210CriticalrawmaterialinvivopharmacodynamicsPre-INDCertificateofAnalysisUS Food andDrugAdministration(USFD/FDA)PotencyToxicityDrugproductBatchrecordsEndpointPre-NDAPhase3BatchRecordsBioavailabilitybenefit-riskprofileEnd-of-Phase 2AMeetings(EoP2)QualityAssuranceOrphandrugdesignation(ODD)Free!AllogeneicDrugMasterFile(DMF)SterilityOncologicDrugsAdvisoryCommittee(ODAC)SafetyPharmacologyInvestigationalNew DrugApplication(IND)ImmunogenicFDAExpeditedPrograms orFast-TrackreviewActivePharmaceuticalIngredient (API)DrugsubstanceOpen-labelTeratogenicityInternationalConferenceonHarmonization(ICH)Proof-of-ConceptAbbreviatedNew DrugApplication(ANDA)pharmacokineticsPhase2CRISPRBiologicsLicenseApplication(BLA)ISO5SpecificityQualityControlexvivoOut ofSpec(OOS)ISO8NewChemicalEntity(NCE)Phase1Confidentialityagreement(CDA)ISO9001BioequivalenceNon-disclosureagreement(NDA)Center forDrugEvaluationand Research(CDER)CarcinogenicityPurityPre-ClinicalChemistryManufacturingControls(CMC)FunctionalityIdentityDeviationStabilityINitial TargetedEngagement forRegulatoryAdvice CBERproducTs(INTERACT)505(b)(1)vs.505(b)(2)efficacysingleascendingdoseISO7AdverseeventCenter forBiologicsEvaluationand Research(CBER)21 CFRPart 31221 CFRPart 11EuropeanMedicinsAgency(EMA)21 CFRPart 210CriticalrawmaterialinvivopharmacodynamicsPre-INDCertificateofAnalysisUS Food andDrugAdministration(USFD/FDA)PotencyToxicityDrugproductBatchrecordsEndpointPre-NDAPhase3BatchRecordsBioavailabilitybenefit-riskprofileEnd-of-Phase 2AMeetings(EoP2)QualityAssuranceOrphandrugdesignation(ODD)Free!AllogeneicDrugMasterFile(DMF)SterilityOncologicDrugsAdvisoryCommittee(ODAC)SafetyPharmacologyInvestigationalNew DrugApplication(IND)ImmunogenicFDAExpeditedPrograms orFast-TrackreviewActivePharmaceuticalIngredient (API)DrugsubstanceOpen-labelTeratogenicityInternationalConferenceonHarmonization(ICH)Proof-of-ConceptAbbreviatedNew DrugApplication(ANDA)pharmacokineticsPhase2CRISPRBiologicsLicenseApplication(BLA)

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
  1. ISO 5
  2. Specificity
  3. Quality Control
  4. ex vivo
  5. Out of Spec (OOS)
  6. ISO 8
  7. New Chemical Entity (NCE)
  8. Phase 1
  9. Confidentiality agreement (CDA)
  10. ISO 9001
  11. Bioequivalence
  12. Non-disclosure agreement (NDA)
  13. Center for Drug Evaluation and Research (CDER)
  14. Carcinogenicity
  15. Purity
  16. Pre-Clinical
  17. Chemistry Manufacturing Controls (CMC)
  18. Functionality
  19. Identity
  20. Deviation
  21. Stability
  22. INitial Targeted Engagement for Regulatory Advice CBER producTs (INTERACT)
  23. 505(b)(1) vs. 505(b)(2)
  24. efficacy
  25. single ascending dose
  26. ISO 7
  27. Adverse event
  28. Center for Biologics Evaluation and Research (CBER)
  29. 21 CFR Part 312
  30. 21 CFR Part 11
  31. European Medicins Agency (EMA)
  32. 21 CFR Part 210
  33. Critical raw material
  34. in vivo
  35. pharmacodynamics
  36. Pre-IND
  37. Certificate of Analysis
  38. US Food and Drug Administration (USFD/FDA)
  39. Potency
  40. Toxicity
  41. Drug product
  42. Batch records
  43. Endpoint
  44. Pre-NDA
  45. Phase 3
  46. Batch Records
  47. Bioavailability
  48. benefit-risk profile
  49. End-of-Phase 2A Meetings (EoP2)
  50. Quality Assurance
  51. Orphan drug designation (ODD)
  52. Free!
  53. Allogeneic
  54. Drug Master File (DMF)
  55. Sterility
  56. Oncologic Drugs Advisory Committee (ODAC)
  57. Safety
  58. Pharmacology
  59. Investigational New Drug Application (IND)
  60. Immunogenic
  61. FDA Expedited Programs or Fast-Track review
  62. Active Pharmaceutical Ingredient (API)
  63. Drug substance
  64. Open-label
  65. Teratogenicity
  66. International Conference on Harmonization (ICH)
  67. Proof-of-Concept
  68. Abbreviated New Drug Application (ANDA)
  69. pharmacokinetics
  70. Phase 2
  71. CRISPR
  72. Biologics License Application (BLA)